Top Markets
Coin of the day
RegeneRx Biopharmaceuticals, Inc. RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc.

RGRX
株式のランク #42502
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the... RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.
株価
$0.0007
最終同期: 2026-08-11
時価総額
$1.05K
変化(1日)
0.00%
変化(1年)
250.00%
US
取引 RegeneRx Biopharmaceuticals, Inc. (RGRX)

カテゴリー

RegeneRx Biopharmaceuticals, Inc.(RGRX)の収益
Aug 2026 時点の収益 TTM: 0
RegeneRx Biopharmaceuticals, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
RegeneRx Biopharmaceuticals, Inc. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
- -
CH
$10.11B -
BE
- -
KR